The fiscal cliff has been described as a potential disaster for the finances of individuals and corporations alike. If Congress and the White House do not reach an agreement on the budget…
Short sellers are still active in the high-dividend names out there. Apparently many are under the impression that the dividend bubble is worth betting against. Still, it takes keen conviction to short…
Short sellers appear to be increasing their bets against some of the key dividend stocks we track each and every day, judging by the August 15 settlement date for the short interest…
Jon OggThese are the top analyst calls of upgrades, downgrades and initiations we have seen from Wall St. research calls this Friday morning. Abercrombie & Fitch Co. (NYSE: ANF) maintained…
U.S. stocks are poised to open higher as investors await the first reading on second-quarter U.S. GDP, and after encouraging remarks from Europe’s central bank about supporting the euro. Economists predict the…
The three major US stock indexes opened higher this morning following European Central Bank president Mario Draghi’s promise to “do whatever it takes to preserve the euro” (our coverage here). What he…
GileadGilead Sciences, Inc. (NASDAQ: GILD) has a product chest that includes Atripla, Truvada, Viread, Complera/Eviplera, and Emtriva for the treatment of HIV infection in adults. While Gilead has been diversifying its products…
Online drug research firm drugs.com today released its list of the top 100 selling drugs in the United States for the first quarter of 2012. The top five sellers include drugs from…
Abbott Laboratories (NYSE: ABT) reported second-quarter results this morning that beat the consensus estimate for earnings per share (EPS), but missed slightly on revenues. The drug maker reported adjusted diluted EPS of…
What usually happens when you get two mergers announced in drugs and biotech in the same day? Investors begin to wonder which other peers and competitors might be on the M&A block.…
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Thursday. There are many reports this morning! ADTRAN Inc. (NASDAQ: ADTN) Cut to Hold…
More biotech mergers are on the way! That is the verdict of Wall St. There may be patent protection risks associated with future regulation under health care, but deals in the biotech…
Some mergers are very straight-forward, and others are just odd. Now we have an answer over whether or not Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) was going to be acquired or not. Bristol-Myers…
The three major US stock indexes opened lower this morning as markets have begun to reach the conclusion that this week’s Eurozone summit is not likely to resolve the continent’s financial crisis.…
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Monday. ABB Ltd. (NYSE: ABB) Cut to Underweight at JPMorgan. Alaska Air Group…
